Search Results
Mar 30, 2026, 08:00 ET The IAMS™ Brand Delivers Whole-Body Health for "Smooth Deliveries" at Home
multimedia:https://www.prnewswire.com/news-releases/the-iams-brand-delivers-whole-body-health-for-smooth-deliveries-at-home-302727766.htmlSOURCE
More news about: The IAMS™ Brand
Mar 30, 2026, 08:00 ET Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a
More news about: AbbVie
Mar 30, 2026, 07:30 ET Spring Starts in the Bedroom: PHF Unveils Performance-Driven Breathable Bedding Collection for 2026
fabric engineering focuses on microclimate regulation at the skin level. The breathable weave structures promote continuous airflow, helping stabilize body temperature and reduce heat buildup—two key factors linked to sleep disruption. By managing moisture and temperature simultaneously, the collection
More news about: PHF
Mar 30, 2026, 06:14 ET AGIBOT Reaches 10,000 Units as Real-World Demand for Robots Accelerates
general-purpose embodied robot products and an application ecosystem. Built on the foundation of the robotic body and powered by the fusion of interaction, manipulation, and locomotion intelligence — "1 Robotic Body + 3 Intelligence" — AGIBOT is a leading robotics company in the industry to deliver a complete product
More news about: AGIBOT
Mar 30, 2026, 04:32 ET AGIBOT Reaches 10,000 Units as Real-World Demand for Robots Accelerates
general-purpose embodied robot products and an application ecosystem. Built on the foundation of the robotic body and powered by the fusion of interaction, manipulation, and locomotion intelligence — "1 Robotic Body + 3 Intelligence" — AGIBOT is a leading robotics company in the industry to deliver a complete
More news about: AGIBOT
Mar 30, 2026, 03:43 ET Trab Health Launches Luminara, A Holistic Women's Wellness Supplement For The Demands Of Daily Life
modern life can affect energy, mood, sleep and overall vitality," said Bart Jarvis, founder and CEO of Trab Health. "Luminara was created to support the body as an interconnected system, recognizing that a woman's well-being is shaped by factors including stress, cardiovascular health, nervous system balance
More news about: Trab Health
Mar 30, 2026, 02:23 ET EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "Sobi's marketing authorisation application reflects the growing body of clinical evidence supporting Tryngolza and our commitment to improving treatment options for people living with sHTG."Olezarsen is developed
More news about: Swedish Orphan Biovitrum AB
Mar 29, 2026, 23:30 ET Singclean Global Aesthetic Master Symposium Makes Landmark Debut in Monaco
Singderm: Sculpting the Body, Defining the ArtOn March 27, Dr. Roberto Chacur, author of the book Science and Art of the Filler, delivered a session titled "HA for Gluteal
More news about: Hangzhou Singclean Medical Products Co.,Ltd.
Mar 29, 2026, 11:00 ET PureHealth Research: Why Extremity Numbness Is Rising - And How Botanical Circulation Health Supplements May Help
circulation health supplements at PureHealth Research and discover how targeted botanical nutrition may promote the circulation your body depends on.PureHealth Research [email protected]+1
More news about: PureHealth Research LLC
Mar 29, 2026, 10:00 ET Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment
patients whose commitment to advancing science made the ALL-RISE Trial possible. The positive results from this landmark study add to an already robust body of clinical evidence generated from thousands of patients treated globally according to FFRangio guidance, reinforcing the distinct advantages that
More news about: CathWorks
Mar 29, 2026, 10:00 ET Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment
patients whose commitment to advancing science made the ALL-RISE Trial possible. The positive results from this landmark study add to an already robust body of clinical evidence generated from thousands of patients treated globally according to FFRangio guidance, reinforcing the distinct advantages that
More news about: CathWorks
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for
More news about: Amgen
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
peptide-1) receptor agonist obesity medication. Zepbound lowers body weight by decreasing calorie intake and appetite. Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or
More news about: Eli Lilly and Company
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
RezpegaldesleukinAutoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin
More news about: Nektar Therapeutics
Mar 28, 2026, 10:55 ET CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
taking their medications consistently, significantly increasing their risk of stroke.4 The CHAMPION-AF data add to Boston Scientific's robust body of clinical evidence supporting the WATCHMAN device as a one-time implant that helps provide stroke risk protection over a patient's lifetime."More
More news about: Boston Scientific Corporation
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.b. The PASI score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness. PASI 100 corresponds to an improvement
More news about: Johnson & Johnson
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 2.5% of the United States and global population during their lifetime. The scalp is the most commonly affected area,
More news about: Sun Pharma
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
than those meeting moderate treatment targets (21.7%) or neither treatment target (9.9%).Additionally, in evaluating outcomes across body regions, more than half of patients achieved EASI-90 in the head and neck region after six months of upadacitinib treatment, with consistent responses
More news about: AbbVie
Mar 27, 2026, 09:46 ET LifeQuotes.com Reveals Best Life Insurance Rates for Multiple Sclerosis (MS) Patients - Our Top Picks for 2026
Society, MS is an "unpredictable, often disabling disease of the central nervous system that disrupts the flow of information between the brain and body." With MS, the immune system mistakenly attacks myelin, a fatty substance that protects nerve fibers called axons. The axons' protective coverings become
More news about: Life Quotes, Inc.
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
Cell-in-a-Box® encapsulation platform, which packages living cells inside a pin-head-sized, sphere-shaped protective capsule so they can be implanted inside the body and continue producing a target protein over time. The end goal is a cell-based therapy that restores circulating Klotho levels in patients, potentially
More news about: USA News Group
Mar 27, 2026, 09:03 ET OLAY Unveils Proprietary Research on Cell Adhesion as a Key Driver of Skin Aging at AAD 2026
help support skin's natural collagen, strengthen cellular bonds and deliver visible results without needles, lasers or downtime.Together, this body of research cements OLAY's leadership in the science of cellular aging and its continued focus on identifying new biological pathways — like cell adhesion
More news about: OLAY
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
remission in psoriasis has recently emerged: continuous maintenance of either body surface area (BSA)=0% for ≥6 months or Investigator's Global Assessment (IGA)=0 for ≥6 months while on treatment1BSA (body surface area): Widely known and used measure of the extent of psoriasis
More news about: UCB
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
subgroups: age (<35 years vs ≥35 years), sex, median disease duration at baseline (<5.02, ≥5.02 years), severity assessed by Hurley Stage (II, III), body mass index (<30 kg/m2, 30–<35 kg/m2, ≥35 kg/m2).3* BIMZELX was associated with efficacy improvements
More news about: UCB
Mar 27, 2026, 08:12 ET HONOR2U Redefines Safety and Equity with "Honor 2 Her" Initiative for Women in Public Service
women in law enforcement, firefighting, and emergency services. The program disrupts the history of women adapting to equipment designed for the male body by building gear with female frontline professionals. In 2025, the first-ever national survey of police uniforms in England and Wales,
More news about: HONOR2U
Mar 27, 2026, 07:56 ET Colgate Total Partners with Mumbai Indians; PLOT Initiative Rolled Out to Maintain Peak Dental Health
is a critical determinant of a player's on-field endurance and recovery.The mouth is a gateway to the body. Backed by scientific evidence, germs in a person's mouth can enter the body, causing inflammation which slows down recovery, impacting athletic performance. Hence, on the field where peak
More news about: Colgate-Palmolive India